Abstract
The essential role of prolactin (PRL) in normal mammary gland growth and differentiation has implicated this hormone in the development and progression of breast cancer. Although Stat5 is the best-characterized mediator of PRL signals, PRL also activates multiple other signals, whose roles in normal and pathologic processes are not well understood. We have shown that PRL stimulates activating protein-1 (AP-1) activity in breast cancer cells, and can cooperate with estradiol in this pathway. AP-1 modulates many processes critical for carcinogenesis, including cell proliferation, survival, transformation, invasion and angiogenesis, and is elevated in many neoplasms, including breast tumors. Here, we investigated the relationship between PRL signals to AP-1 and Stat5. We found that PRL activation of Stat5a and Stat5b, but not Stat1 or Stat3, reduced PRL signals to AP-1, without altering estradiol-induced AP-1 activity. The truncation mutant, Stat5/Δ53C, but not Stat5Y699F, was an effective inhibitor, consistent with a requirement for Stat5 dimerization and nuclear accumulation, but not its C-terminal transactivation activity. The association of Stat5 with AP-1 proteins suggests that this underlies the inhibition. Predictably, the ability of PRL to activate Stat5 and AP-1 was inversely related in mammary cell lines. Further, reduction of Stat5 protein with siRNA in T47D cells, which contain elevated Stat5, increased PRL-induced AP-1 signals, transcripts for the AP-1 target, matrix metalloproteinase-2 and associated invasive behavior. This study points to the importance of cell context in determining the spectrum of PRL-induced actions, which is critical for understanding the contributions of PRL to breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bjornstrom L, Sjoberg M . (2002). STAT as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16: 2202–2214.
Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ . (1995). Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706–718.
Brockman JL, Schroeder MD, Schuler LA . (2002). Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 16: 774–784.
Bromberg J . (2002). Stat proteins and oncogenesis. J Clin Invest 109: 1139–1142.
Buettner R, Mora LB, Jove R . (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945–954.
Cao JS, Wood M, Liu Y, Hoffman T, Hyde J, Park-Sarge OK et al. (2004). Estradiol represses prolactin-induced expression of Na+/taurocholate cotransporting polypeptide in liver cells through estrogen receptor-α and STAT5a. Endocrinology 145: 1739–1749.
Clevenger CV, Furth PA, Hankinson SE, Schuler LA . (2003). Role of prolactin in mammary carcinoma. Endocr Rev 24: 1–27.
Cotarla I, Ren SX, Zhang Y, Gehan E, Singh B, Furth PA . (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665–671.
DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG et al. (1996). Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol 117: 131–140.
Eferl R, Wagner EF . (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859–868.
Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA . (2001). Cross-talk between ERs and Stat5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15: 1929–1940.
Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI . (2000). Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89: 177–186.
Goffin V, Bernichtein S, Touraine P, Kelly PA . (2005). Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26: 400–422.
Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA . (2005). Prolactin and estrogen enhance the activity of AP-1 in breast cancer cells: role of ERK1/2-mediated signals to c-fos. Mol Endocrinol 19: 1765–1778.
Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA . (2004). Multiple kinase cascades mediate prolactin signals to AP-1 in breast cancer cells. Mol Endocrinol 18: 3064–3075.
Hennighausen L, Robinson GW . (2005). Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715–725.
Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM et al. (1997). Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94: 1074–1079.
Humphreys RC, Hennighausen L . (1999). STAT5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685–694.
Iavnilovitch E, Groner B, Barash I . (2002). Overexpression and forced activation of Stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Cell Growth Differ 1: 32–47.
Ilaria Jr RL, Hawley RG, Van Etten RA . (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154–4166.
Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al. (1999). Increased AP-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256.
Keely PJ . (2001). Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. Methods Enzymol 333: 256–266.
Levy DE, Darnell Jr JE . (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.
Luo GY, Yu-Lee LY . (2000). Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14: 114–123.
Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T . (2000). Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of AP-1 family members. Int J Cancer 87: 468–472.
Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A et al. (2004). The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86: 139–152.
Nakamura T, Ouchida R, Kodama T, Kawashima T, Makino Y, Yoshikawa N et al. (2002). Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba/F3 cells. J Biol Chem 277: 6254–6265.
Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. (2004). Stat-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053–2060.
Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S . (2006). Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 66: 1824–1832.
Ormandy CJ, Horseman ND, Naylor MJ, Harris J, Robertson F, Binart N et al. (2001). Mammary gland development. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 219–232.
Ren S, Cai HR, Li M, Furth PA . (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 4335–4339.
Schroeder MD, Symowicz J, Schuler LA . (2002). Prolactin modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16: 45–57.
Shaulian E, Karin M . (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131–E136.
Shemanko CS, Groner B . (2001). Transcription factors, cofactors and target genes mediating prolactin signals. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 381–404.
Shuai K . (2000). Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19: 2638–2644.
Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H . (2005). Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24: 746–760.
Tworoger SS, Hankinson SE . (2006). Prolactin and breast cancer risk. Cancer Lett 243: 160–169.
Van't Veer LJ, Dai HY, Van de Vijver MJ, He YDD, Hart AAM, Mao M et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
Vincenti MP . (2001). The matrix metalloproteinase and tissue inhibitor of metalloproteinase genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 151: 121–148.
Vonderhaar BK . (2000). Prolactin in Human Breast Cancer Development. Endocrine Oncology In: Ethier SP (ed). Humana Press: Totowa, NJ, pp. 101–120.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. (2005). Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671–679.
Watson CJ . (2001). Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 115–127.
Weaver AM, Silva CM . (2006). Modulation of Stat5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. Mol Endocrinol 20: 2392–2405.
Yang E, Lerner L, Besser D, Darnell Jr JE . (2003). Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278: 15794–15799.
Zhang X, Wrzeszczynska MH, Horvath CM, Darnell Jr JE . (1999). Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19: 7138–7146.
Acknowledgements
We appreciate the plasmids provided by Drs C Clevenger, RL Ilaria, E Kabotyanski and J Rosen, and the assistance of Dr P Keely, A Guadarrama and Dr G Wiepz with the invasion assays. This work was supported in part by NIH R01 CA78312 and DK07623 (LAS), and DAMD17-01-1-0460 (JHG).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Gutzman, J., Rugowski, D., Nikolai, S. et al. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene 26, 6341–6348 (2007). https://doi.org/10.1038/sj.onc.1210454
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210454
Keywords
This article is cited by
-
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells
Breast Cancer Research (2017)
-
Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells
Molecular and Cellular Biochemistry (2015)
-
Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer
Breast Cancer Research and Treatment (2013)
-
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer
Breast Cancer Research (2011)
-
Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer
Breast Cancer Research (2011)